The announcement by the Secretary of State for Health of the merger of the National Biological Standards Board with the Health Protection Agency (HPA) has been welcomed by both bodies.
Sir William Stewart, chairman of the HPA said, There are already considerable synergies between the two bodies particularly in the area of infectious diseases and their control.
The National Institute for Biological Standards and Control has a deserved world-wide reputation for the excellence of its product analyses, production and control. The Health Protection Agency is a global first as a one-stop shop dedicated to protecting the health of the general public from infections, chemicals, poisons and radiation.
Both organizations have to operate against an increasingly global backdrop, and I am sure that harnessing the collective expertise of both will benefit public health protection in the United Kingdom and also its industrial competitiveness in the burgeoning life sciences arena of the 21st Century.
Professor Gordon Duff, chairman of the National Biological Standards Board said, Modern biology promises innovative medicines for the prevention and treatment of diseases, but there are new problems as well. The safety of biological medicines, emerging diseases, antibiotic resistance, global epidemics and the threat of bioterrorism are among the challenges to be met. This merger with the HPA creates an organization with a wide range of relevant expertise, and a coordinated approach to safeguarding public health.
Source: HPA
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.